251
|
Jhaveri KL, Patil S, Khasraw M, Bhatia J, Stadler ZK, Kauff ND, Hudis C, Offit K, Robson ME. Risk of breast cancer (BC) after BRCA-mutation associated ovarian cancer (BRCA-OC): Memorial Sloan-Kettering Cancer Center (MSKCC) experience. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
252
|
Morris PG, Fazio M, Jhaveri KL, Serna-Tamayo C, Eaton A, Patil S, Ulaner G, Howard J, Larson SM, Hudis C, Jochelson MS, McArthur HL. Standardized uptake value (SUV) by positron emission tomography/computed tomography (PET/CT) as a prognostic variable in metastatic breast cancer (MBC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
253
|
Malik NK, Warren GW, Yang G, Zeeck K, Papsidero T, Patil S, Khushalani NI, Sher T, Yendamuri SS, Nava HR, Salerno May K. Response-based outcomes in patients with esophageal cancer treated with primarily non-cisplatin and 5-fluorouracil–based trimodality therapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
254
|
Voss MH, Jacobsen EP, Patil S, Turkula S, Jia X, Sheinfeld J, Bajorin DF, Bosl GJ, Motzer RJ, Feldman DR. Clinical features of germ cell tumors (GCT) in men age 50 or older: Successful outcome and tolerability to chemotherapy for advanced disease. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
255
|
Salerno May K, Malik NK, Yang G, Patil S, Flaherty L, Khushalani NI, Sher T, Yendamuri SS, Nava HR, Warren GW. The effect of smoking history on response and survival outcomes patients with in esophageal cancer treated with neoadjuvant concurrent chemoradiotherapy followed by surgery. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
256
|
Gucalp A, Tolaney SM, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell KL, Rugo HS, Nabell L, Abbruzzi A, Gonzalez J, Giri DD, Patil S, Feigin K, D'Andrea G, Theodoulou M, Drullinsky P, Sklarin NT, Hudis C, Traina TA. TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR- metastatic breast cancer (MBC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps122] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
257
|
Thodima VJ, Molina AM, Jia X, Zhang J, Georges ME, Patil S, Reuter VE, Motzer RJ, Chaganti RS. Molecular classification of sunitinib response in metastatic renal cell carcinoma (mRCC) patients by gene expression profiling. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4556] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
258
|
Oppong B, Oskar S, Stempel M, Eaton A, Patil S, King TA. Does metformin use influence outcome in diabetic women with invasive breast cancer? J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
259
|
Molina AM, Jia X, Ginsberg MS, Velasco S, Feldman DR, Patil S, Motzer RJ. Long-term response to sunitinib for metastatic renal cell carcinoma (mRCC) patients treated on clinical trials at Memorial Sloan-Kettering Cancer Center. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4615] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
260
|
Patil S, Manola J, Elson P, Bro W, Negrier S, Escudier B, Bukowski RM, Motzer RJ. Risk factor migration and survival: Analysis from international dataset of 3,748 metastatic renal cell carcinoma (mRCC) patients treated on clinical trials. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
261
|
Dang CT, Morris PG, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Norton L, Hudis C. Long-term cardiac safety and outcomes of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
262
|
Patil S, Valdramidis VP, Karatzas KAG, Cullen PJ, Bourke P. Assessing the microbial oxidative stress mechanism of ozone treatment through the responses of Escherichia coli mutants. J Appl Microbiol 2011; 111:136-44. [PMID: 21457413 DOI: 10.1111/j.1365-2672.2011.05021.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
AIMS To investigate the effect of the oxidative stress of ozone on the microbial inactivation, cell membrane integrity and permeability and morphology changes of Escherichia coli. METHODS AND RESULTS Escherichia coli BW 25113 and its isogenic mutants in soxR, soxS, oxyR, rpoS and dnaK genes were treated with ozone at a concentration of 6 μg ml⁻¹ for a period up to 240 s. A significant effect of ozone exposure on microbial inactivation was observed. After ozonation, minor effects on the cell membrane integrity and permeability were observed, while scanning electron microscopy analysis showed slightly altered cell surface structure. CONCLUSIONS The results of this study suggest that cell lysis was not the major mechanism of microbial inactivation. The deletion of oxidative stress-related genes resulted in increased susceptibility of E. coli cells to ozone treatment, implying that they play an important role for protection against the radicals produced by ozone. However, DnaK that has previously been shown to protect against oxidative stress did not protect against ozone treatment in this study. Furthermore, RpoS was important for the survival against ozone. SIGNIFICANCE AND IMPACT OF THE STUDY This study provides important information about the role of oxidative stress in the responses of E. coli during ozonation.
Collapse
|
263
|
Patil S, Bhaskar P, Sudheer S. Design and Implementation of an Integrated Fuzzy Logic Controller for a Multi-input Multi-output System. DEFENCE SCI J 2011. [DOI: 10.14429/dsj.61.24] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
264
|
Molina AM, Feldman DR, Ginsberg MS, Fischer P, Trinos MJ, Patil S, Motzer RJ. Phase I trial sunitinib plus everolimus in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.311] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
311 Background: Sunitinib a targeted tyrosine kinase inhibitor and everolimus an mTOR inhibitor both inhibit hypoxia-induced factor-dependent signaling and have activity in advanced renal cell carcinoma (RCC). The safety and maximum tolerated dose (MTD) of sunitinib in combination with everolimus was assessed in this phase I trial. Methods: Cohorts of 3–6 patients with mRCC received sunitinib at 37.5 or 50 mg daily for 4 weeks followed by 2 weeks off with everolimus administered either daily (2.5 or 5 mg) or weekly (20 or 30 mg). Dose-limiting toxicities (DLTs) were assessed in the first 6-week cycle to determine MTD. Results: 20 patients (13 clear cell and 7 non-clear cell RCC) were enrolled in five cohorts. Both patients in the 2nd dose level (everolimus 5 mg daily, sunitinib 37.5mg) experienced grade 3 DLT (thrombocytopenia and mucositis; vomiting). With weekly everolimus dosing, the MTD was everolimus 30 mg /sunitinib 37.5 mg (4th dose level). However, only one of six patients at this dose level tolerated treatment beyond 4 cycles. Grades 3 and 4 toxicities observed with chronic treatment included infection, gastrointestinal hemorrhage, and pulmonary embolism. A total of six patients were treated with everolimus 20b mg weekly/37.5 mg sunitinib (3rd dose level) with better tolerance as chronic therapy. Overall, 5 out of 20 patients achieved a partial response including 3 patients with non-clear cell histology. Conclusions: Partial responses were observed in both clear cell and non-clear cell histologies. However, due to toxicity the combination of sunitinib and everolimus could not be administered at full doses. [Table: see text]
Collapse
|
265
|
Prabhash K, Nag S, Patil S, Parikh PM. Optimising management of cancer related anemia. Indian J Cancer 2011; 48:1-10. [PMID: 21330748 DOI: 10.4103/0019-509x.76622] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
This review article provides the current recommendations and evidence for the correct management of anemia in cancer patients. The various options available include transfusions, iron and erythropoiesis stimulation. The indications, pros and cons of each option are discussed.
Collapse
|
266
|
Blumenthal K, Patil S, Ling M, Long A. The Importance of Vancomycin in Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome. J Allergy Clin Immunol 2011. [DOI: 10.1016/j.jaci.2010.12.787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
267
|
Patil S. A comparison of IMRT and 3DCRT in the treatment planning of patients with distal esophageal cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
143 Background: There is limited data comparing intensity modulated radiation therapy (IMRT) and 3D conformal radiation therapy (3DCRT) in node-negative patients with cancer of the distal esophagus. Methods: Eight patients with node-negative cancer of the distal esophagus measuring 1-5 cm tumors were selected for this study. Target volumes were generated for all patients based on standard current practice; 3DCRT and IMRT plans optimized to obtain minimum dose to the heart were then created using the using the Eclipse Treatment Planning. Conformality index (CI, the amount of target volume covered by the prescription dose) and conformation number (CN, the amount of normal tissue receiving prescription dose) were calculated. Dose volume histograms also were generated and clinically relevant parameters were extracted and compared for each planning modality using paired T-tests. Each patient served as his or her own control. Results: The difference in CI ranged from 0-0.01, indicating equivalent target coverage for each patient. IMRT produced superior CN (mean CN = 0.74) vs. the 3DCRT plans (mean CN = 0.45). Heart V40 and the maximum dose to spinal cord were lower for IMRT (mean difference in heart V40 = 34.5%, p=0.0006 and mean difference in the maximum dose to the spinal cord = 18.1 Gy, p=0.0005) but lung V5 and V20 were lower for 3DCRT (mean difference in lung V5 = -21.3%, p=0.0026 and mean difference in lung V20 = -5.2%, p=0.0014). Conclusions: When optimized to minimize dose to the heart, IMRT plans were substantially more conformal to the target structures with less dose to the heart as compared to 3DCRT plans; however this occurred at the expense of increased dose delivered to the lung. No significant financial relationships to disclose.
Collapse
|
268
|
Patil S, Ling M, Wilson M, Long A, Hesterberg P, Wong J, Banerji A. Repeat Skin Testing Improves Risk Stratification For Platinum-based Chemotherapy Desensitizations. J Allergy Clin Immunol 2011. [DOI: 10.1016/j.jaci.2010.12.569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
269
|
Deshmukh MB, Patil S, Patil SS, Jadhav SD. Synthesis and Antimicrobial Screening of Pyrazolo-3-Aryl Quinazolin-4(3H)ones. Indian J Pharm Sci 2011; 72:500-4. [PMID: 21218064 PMCID: PMC3013576 DOI: 10.4103/0250-474x.73934] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2009] [Revised: 03/02/2010] [Accepted: 08/01/2010] [Indexed: 11/09/2022] Open
Abstract
2-thio-3-aryl quinazolin-4(3H)one (1) was synthesized by reacting anthranilic acid with thiocarbamate salts of substituted aniline and carbon disulphide, which on reflux with excess of hydrazine hydrate to form 2-hydrazino quinazolin-4(3H)one derivatives (2). The reaction of (2) with variously substituted aryl aldehydes gave the corresponding hydrazones (3). Further, the cyclization of compound (3) in acetic anhydride gave tricyclic pyrazoloquinazolinones (4). All newly synthesized compounds have been tested for their antibacterial activity against gram +ve bacteria B. substilis, S. aureus and gram –ve bacteria E. coli, P. vulgaris. The species used for antifungal activity are Aspergillus niger and Phytophora. Introduction of -OCH3, -OH and -Cl groups to the heterocyclic frame work enhanced antibacterial and antifungal activities.
Collapse
|
270
|
Patil S, Valdramidis VP, Tiwari BK, Cullen PJ, Bourke P. Quantitative assessment of the shelf life of ozonated apple juice. Eur Food Res Technol 2011. [DOI: 10.1007/s00217-010-1416-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
271
|
Issa-El-Khoury K, Bayuk JL, Patil S, Ling M, Long A, Hesterberg P, Ling M, Patil S, Banerji A, Rork JF, Sheehan WJ, Gaffin JM, Timmons KG, Sidbury R, Schneider LC, Phipatanakul W, Cortot CF, Sheehan WJ, Baxi SN, Dioun AF, Schneider LC, Phipatanakul W. Research abstracts presented at the Fall Meeting of the New England Society of Allergy, October 23-24, 2010, Woodstock, Vermont. Allergy Asthma Proc 2011; 32:80-81. [PMID: 29165195 DOI: 10.2500/108854111794365133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
272
|
Sancheti KH, Sancheti PK, Shyam AK, Patil S, Dhariwal Q, Joshi R. Authors' reply. Indian J Orthop 2011; 45:381-2. [PMID: 21772637 PMCID: PMC3134029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|
273
|
Patil S, Bhayani S, Denton JM, Nolan J. Therapeutic hypothermia for out-of-hospital cardiac arrest: implementation in a district general hospital emergency department. Emerg Med J 2010; 28:970-3. [DOI: 10.1136/emj.2010.091439] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
274
|
Morris PG, Abbruzzi A, D'Andrea G, Gilewski T, Lake D, Bromberg J, Dang C, Dickler M, Modi S, Seidman AD, Sklarin N, Chang J, Patil S, Norton L, Hudis CA, Fornier MN. Abstract P6-12-09: A Phase I-II Trial of Dasatinib (D) in Combination with Weekly (w) Paclitaxel (P) for Patients (Pts) with Metastatic Breast Carcinoma (MBC). Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p6-12-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Inhibition of SRC is a novel approach for MBC. D is an inhibitor of multiple tyrosine kinases, including the SRC family. Pre-clinical data show D inhibits multiple breast cancer cell lines, including those of “basal-like” subtype. In preclinical models D + P had superior antitumor activity to either agent alone. We designed this phase I-II study to translate this observation.
Methods: For phase I: pts with MBC, ECOG PS 0-1, normal hepatic, renal, marrow function were eligible. Pts with pleural/pericardial effusions were excluded. For phase II: pts had measurable, HER2-negative MBC, ≥2 prior rx for MBC. Prior taxanes, stable brain metastases and baseline neuropathy grade ≥1 were allowed. Cycle (C) consisted of wP 80 mg/m2 IV 3/4 weeks + D 70mg orally daily; escalating to 100 mg, 120 mg and 150 mg in cohorts of 3pts. Toxicity was assessed by CTCAE v3.0, response by RECIST.
Results: 17 pts enrolled (15 phase I; 2 phase II); median age 54 (range 35-74), median PS=1 (range 0-1). 12 (71%) pts rcvd prior adjuvant chemoRx. Pts rcvd a median of 3 prior rx for MBC (range 0-12). Pts rcvd median of 2 C of D + P (range 1-14). One DLT occurred at 150mg (G3 fatigue); this cohort was expanded with no further DLTs. However 3 pts on this dose level withdrew;1 pt delayed hypersensitivity rash (grade 1), 1 pt febrile neutropenia (grade 3), 1 pt paclitaxel pneumonitis (grade 3). Therefore the phase II dose is D 120mg. Overall the most common toxicities have been hematologic and low G (table). 13 pts are assessable for response; 4 patients (31%) had a PR, including 3 patients previously treated with taxanes. 5 pts (29%) had stable disease.
Toxicities > Grade 1
Conclusion: Treatment with wP and D is feasible in pts with MBC. In the phase I study, 1 DLT occurred at D 150mg but due to cumulative toxicities the recommended dose for the ongoing phase II study is 120mg. Preliminary evidence of activity has been seen in taxane-pretreated pts at the phase II dose. Identification of biomarkers to select appropriate pts for this therapeutic approach is the subject of ongoing correlative studies.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P6-12-09.
Collapse
|
275
|
Rakha EA, Patil S, Abdulla K, Abdulkader M, Chaudry Z, Soomro IN. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagn Cytopathol 2010; 38:874-9. [DOI: 10.1002/dc.21303] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|